Stroke News and Research

RSS

A stroke is a medical emergency. Strokes happen when blood flow to your brain stops. Within minutes, brain cells begin to die. There are two kinds of stroke. The more common kind, called ischemic stroke, is caused by a blood clot that blocks or plugs a blood vessel in the brain. The other kind, called hemorrhagic stroke, is caused by a blood vessel that breaks and bleeds into the brain. "Mini-strokes" or transient ischemic attacks (TIAs), occur when the blood supply to the brain is briefly interrupted.

Administering ticagrelor in the ambulance cuts ischaemic events 24 hours following PCI

Ticagrelor administered in the ambulance reduces ischaemic events 24 hours after primary percutaneous coronary intervention (PCI), according to findings from the ATLANTIC-H24 study presented for the first time today at ESC Congress.

1 Sep 2015

SLU scientist receives grant to solve blood-clotting mysteries

Last summer, SLU scientists made a breakthrough discovery about the way in which blood clots. Through X-ray crystallography, they solved the molecular structure of prothrombin, an important blood-clotting protein, revealing an unexpected, flexible role for a "linker" region that may be the key to developing better life-saving drugs.

1 Sep 2015

Study: Retrieval of larger thrombi during IAT linked to improved neurological recovery after acute ischaemic stroke

Retrieval of larger thrombi during intra arterial treatment (IAT) is associated with improved neurological recovery after acute ischaemic stroke, according to a sub study of the MR CLEAN trial presented at ESC Congress today by Dr Anouchska Autar, PhD candidate at the Erasmus Medical Centre in Rotterdam, the Netherlands.

1 Sep 2015

Preoperative statins linked to reductions in cardiac complications, mortality after noncardiac surgery

Preoperative statins are associated with a 17% reduction in cardiac complications and a 43% reduction in mortality after noncardiac surgery, according to results from the VISION Study presented for the first time today at ESC Congress by Dr Otavio Berwanger, director of the Research Institute HCor, Hospital do Coração (Heart Hospital) in São Paulo, Brazil.

1 Sep 2015

GARFIELD-AF Registry: All-cause death is most frequent major event in newly diagnosed AF patients

The first-ever two-year outcomes from the Global Anticoagulant Registry in the Field - Atrial Fibrillation (GARFIELD-AF) showcased at ESC Congress 2015 expose that all-cause death was the most frequent major event in more than 17,000 newly diagnosed AF patients, far exceeding the rate of stroke or major bleeding.

1 Sep 2015

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen Pharmaceuticals, Inc., and its development partner, Bayer HealthCare, today announced results from PMSS (Post-Marketing Safety Surveillance) and XANTUS (XARELTO for Prevention of Stroke in Patients with Atrial Fibrillation), their landmark real-world studies evaluating the safety of XARELTO in people with non-valvular atrial fibrillation (NVAF).

1 Sep 2015

Scientists closer to understanding how neurons are wired to form circuits in the eye

When we move our head, the whole visual world moves across our eyes. Yet we can still make out a bee buzzing by or a hawk flying overhead, thanks to unique cells in the eye called object motion sensors.

1 Sep 2015

DAPT Study shows dual antiplatelet therapy reduces bleeding-related mortality

Fatal bleeding is rare with extended dual antiplatelet therapy, according to a secondary analysis of the DAPT Study presented for the first time today at ESC Congress. Bleeding-related mortality accounted for a minority of deaths in patients treated with dual antiplatelet therapy beyond one year.

1 Sep 2015

Benznidazole has significant antiparasitic activity, but does not reduce progression of Chagas cardiomyopathy

A 40 to 80 day treatment with the antiparasitic medication benznidazole significantly reduced parasite activity in the blood, but not progression, of serious heart problems over a 5-year period among patients with established Chagas disease (CD) cardiomyopathy, results of the BENEFIT trial show.

1 Sep 2015

UC Davis Health System research shows that increasing minimum wage may reduce smoking rates

In addition to restricting when and where tobacco is used at work, UC Davis Health System research shows that employers can do something else to reduce smoking: raise wages.

1 Sep 2015

Study: Inner-city neighbourhoods may affect risk of dying from cardiovascular disease

The inner-city neighbourhood in which someone lives may affect his or her risk of developing or dying from cardiovascular disease, a new research paper suggests.

1 Sep 2015

Elderly patients can benefit from new, minimally invasive surgery for aortic valve replacement

Select patients age 90 years and older with aortic stenosis (AS) can benefit from a relatively new, minimally invasive surgery for aortic valve replacement, according to an article in the September 2015 issue of The Annals of Thoracic Surgery.

1 Sep 2015

Carbonated beverage consumption associated with out-of-hospital cardiac arrests of cardiac origin

Carbonated beverages are associated with out-of-hospital cardiac arrests of cardiac origin, according to results from the All-Japan Utstein Registry presented for the first time today at ESC Congress.

1 Sep 2015

Freespira Breathing System now available for panic disorder treatment through Highmark Health's VITAL program

Highmark Health, Allegheny Health Network and Palo Alto Health Sciences have announced that the Freespira Breathing System is being made available to patients who suffer from panic disorder and symptoms of panic through Highmark Health's new VITAL Innovation Program.

1 Sep 2015

After acute myocardial infarction, respiratory infection associated with increased risk of mortality

Respiratory infection is associated with a four-fold increased risk of in-hospital cardiovascular mortality after acute myocardial infarction (AMI), according to research presented at ESC Congress today by Dr Catarina Quina-Rodrigues, a cardiologist at Hospital de Braga in Portugal. The findings highlight the importance of diagnostic alertness for respiratory infections in AMI patients so that therapeutic measures can be promptly taken.

31 Aug 2015

LCZ696 reduces aortic systolic blood pressure, pulse pressure in hypertensive patients

The combination drug valsartan/sacubitril known as LCZ696 significantly reduced aortic systolic blood pressure and pulse pressure compared to the standard angiotensin receptor blocker (ARB) olmesartan in patients with hypertension, according to results of the PARAMETER study.

31 Aug 2015

Educational program does not influence patients’ adherence to apixaban anticoagulant

Adherence to the oral anticoagulant apixaban among patients with atrial fibrillation (AF) was no better for those who received an educational program compared to those who did not, results of the international, randomised AEGEAN trial show.

31 Aug 2015

TECOS analysis shows sitagliptin safe and effective in patients with type-2 diabetes, cardiovascular disease

Patients with type-2 diabetes and cardiovascular disease can safely take the antihyperglycemic drug sitagliptin without an increased risk of cardiovascular complications - even if they have a history of heart failure - a new analysis of the TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) study shows.

31 Aug 2015

Depression, blood pressure predict harmful vascular events in patients with heart disease, diabetes or stroke

Depressive symptoms and extremes of blood pressure predict the highest rates of harmful vascular events in patients with existing heart disease, diabetes or stroke, according to research presented at ESC Congress today by Dr Bhautesh Jani, clinical academic fellow in the Institute of Health and Wellbeing, University of Glasgow, UK.

31 Aug 2015

ELIXA trial results demonstrate cardiovascular safety of lixisenatide drug

In patients with type 2 diabetes and acute coronary syndrome, the glucose-lowering medication lixisenatide did not increase or decrease the rate of cardiovascular (CV) events compared to placebo, according to results of the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial.

31 Aug 2015

Stroke News and Research

Further Reading

Administering ticagrelor in the ambulance cuts ischaemic events 24 hours following PCI

SLU scientist receives grant to solve blood-clotting mysteries

Study: Retrieval of larger thrombi during IAT linked to improved neurological recovery after acute ischaemic stroke

Preoperative statins linked to reductions in cardiac complications, mortality after noncardiac surgery

GARFIELD-AF Registry: All-cause death is most frequent major event in newly diagnosed AF patients

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Scientists closer to understanding how neurons are wired to form circuits in the eye

DAPT Study shows dual antiplatelet therapy reduces bleeding-related mortality

Benznidazole has significant antiparasitic activity, but does not reduce progression of Chagas cardiomyopathy

UC Davis Health System research shows that increasing minimum wage may reduce smoking rates

Study: Inner-city neighbourhoods may affect risk of dying from cardiovascular disease

Elderly patients can benefit from new, minimally invasive surgery for aortic valve replacement

Carbonated beverage consumption associated with out-of-hospital cardiac arrests of cardiac origin

Freespira Breathing System now available for panic disorder treatment through Highmark Health's VITAL program

After acute myocardial infarction, respiratory infection associated with increased risk of mortality

LCZ696 reduces aortic systolic blood pressure, pulse pressure in hypertensive patients

Educational program does not influence patients’ adherence to apixaban anticoagulant

TECOS analysis shows sitagliptin safe and effective in patients with type-2 diabetes, cardiovascular disease

Depression, blood pressure predict harmful vascular events in patients with heart disease, diabetes or stroke

ELIXA trial results demonstrate cardiovascular safety of lixisenatide drug

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News